Are Analysts Bullish about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) after last week?

April 22, 2018 - By Max Morgan

Investors sentiment decreased to 1.17 in 2017 Q4. Its down 0.26, from 1.43 in 2017Q3. It worsened, as 19 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 39.77 million shares or 2.28% more from 38.89 million shares in 2017Q3 were reported.
Numeric Ltd Liability has invested 0.07% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Deutsche Financial Bank Ag invested in 0% or 112,712 shares. D E Shaw & Commerce stated it has 166,392 shares or 0% of all its holdings. 34,024 are held by State Board Of Administration Of Florida Retirement Sys. Point72 Asset Mngmt Lp invested in 125,000 shares. Quantbot Techs Lp has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Adage Capital Ptnrs Grp invested in 0.01% or 194,541 shares. Prudential reported 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Great West Life Assurance Can owns 9,304 shares. 383,400 were accumulated by Spark Inv Mngmt Lc. Citigroup accumulated 88,871 shares. Schwab Charles Invest Inc holds 0.01% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 482,012 shares. Cadence Capital Mgmt Limited Co holds 0.11% or 109,074 shares in its portfolio. Fmr Ltd Liability has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Pnc Fincl Services Gp reported 400,546 shares.

Since January 2, 2018, it had 0 insider purchases, and 8 selling transactions for $4.89 million activity. Polymeropoulos Mihael Hristos sold $1.14M worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday, February 28. $130,777 worth of stock was sold by Birznieks Gunther on Tuesday, January 2. Shares for $140,494 were sold by Kelly James Patrick.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 3 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 7 analyst reports since October 30, 2017 according to SRatingsIntel. The stock has “Buy” rating by Oppenheimer on Monday, January 8. Oppenheimer maintained the stock with “Buy” rating in Monday, March 5 report. The rating was maintained by Seaport Global with “Buy” on Wednesday, February 28. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Oppenheimer on Sunday, November 12. The stock has “Buy” rating by Jefferies on Tuesday, February 13. Oppenheimer maintained the shares of VNDA in report on Monday, October 30 with “Outperform” rating. Below is a list of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) latest ratings and price target changes.

05/03/2018 Broker: Oppenheimer Rating: Buy New Target: $27.0 Maintain
28/02/2018 Broker: Seaport Global Rating: Buy New Target: $21.0 Maintain
13/02/2018 Broker: Jefferies Rating: Buy New Target: $20.0 Maintain
19/01/2018 Broker: Seaport Global Rating: Buy New Target: $20 Initiates Coverage On
08/01/2018 Broker: Oppenheimer Rating: Buy Maintain
12/11/2017 Broker: Oppenheimer Rating: Buy New Target: $25.0 Maintain
30/10/2017 Broker: Oppenheimer Rating: Outperform Old Target: $21 New Target: $26 Maintain

The stock increased 0.68% or $0.1 during the last trading session, reaching $14.85. About 476,087 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 15.63% since April 22, 2017 and is uptrending. It has outperformed by 4.08% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $756.43 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: